{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:17:56Z","timestamp":1793146676961,"version":"4.5.0"},"reference-count":99,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Introduction:<\/jats:bold>\n                    Etoposide is a broad-spectrum antitumor drug that has been extensively studied in clinical trials. However, limited information is available regarding its real-world adverse reactions. Therefore, this study aimed to assess and evaluate etoposide-related adverse events in a real-world setting by using data mining method on the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    Through the analysis of 16,134,686 reports in the FAERS database, a total of 9,892 reports of etoposide-related adverse drug events (ADEs) were identified. To determine the significance of these ADEs, various disproportionality analysis algorithms were applied, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS) algorithms.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    As a result, 478 significant disproportionality preferred terms (PTs) that were identified by all four algorithms were retained. These PTs included commonly reported adverse events such as thrombocytopenia, leukopenia, anemia, stomatitis, and pneumonitis, which align with those documented in the drug\u2019s instructions and previous clinical trials. However, our analysis also uncovered unexpected and significant ADEs, including thrombotic microangiopathy, ototoxicity, second primary malignancy, nephropathy toxic, and ovarian failure. Furthermore, we examined the time-to-onset (TTO) of these ADEs using the Weibull distribution test and found that the median TTO for etoposide-associated ADEs was 10\u00a0days (interquartile range [IQR] 2\u201332\u00a0days). The majority of cases occurred within the first month (73.8%) after etoposide administration. Additionally, our analysis revealed specific high-risk signals for males, such as pneumonia and cardiac infarction, while females showed signals for drug resistance and ototoxicity.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Discussion:<\/jats:bold>\n                    These findings provide valuable insight into the occurrence of ADEs following etoposide initiation, which can potentially support clinical monitoring and risk identification efforts.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2023.1259908","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T09:23:52Z","timestamp":1698312232000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":59,"title":["A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?"],"prefix":"10.3389","volume":"14","author":[{"given":"Zhiwei","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumeng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"107403","DOI":"10.1016\/j.pharmthera.2019.107403","article-title":"Strategies to generate functionally normal neutrophils to reduce infection and infection-related mortality in cancer chemotherapy","volume":"204","author":"Abdel-Azim","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/sj.clpt.6100258","article-title":"Novel statistical tools for monitoring the safety of marketed drugs","volume":"82","author":"Almenoff","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1089\/jwh.2005.14.19","article-title":"Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics","volume":"14","author":"Anderson","year":"2005","journal-title":"J. Women's Health"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/S1470-2045(18)30500-X","article-title":"Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial","volume":"19","author":"Anderson","year":"2018","journal-title":"Lancet. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3389\/fphar.2019.01161","article-title":"Ototoxic adverse drug reactions: a disproportionality analysis using the Italian spontaneous reporting database","volume":"10","author":"Barbieri","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00002018-200730070-00011","article-title":"Bayesian confidence propagation neural network","volume":"30","author":"Bate","year":"2007","journal-title":"Drug Saf."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1634\/theoncologist.12-9-1044","article-title":"How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries","volume":"12","author":"Blumenfeld","year":"2007","journal-title":"Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1200\/JCO.2001.19.15.3532","article-title":"Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung cancer","volume":"19","author":"Bremnes","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.medcli.2018.10.029","article-title":"Tumour lysis syndrome","volume":"152","author":"Calvo Villas","year":"2019","journal-title":"Med. Clin."},{"key":"B11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","article-title":"Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations","volume":"43","author":"Caster","year":"2020","journal-title":"Drug Saf."},{"key":"B12","doi-asserted-by":"publisher","first-page":"7383","DOI":"10.1158\/1078-0432.CCR-11-1762","article-title":"Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts","volume":"17","author":"Cheema","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41585-022-00683-1","article-title":"High-dose chemotherapy for relapsed testicular germ cell tumours","volume":"20","author":"Chovanec","year":"2023","journal-title":"Nat. Rev. Urol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1200\/JCO.2000.18.9.1867","article-title":"Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia","volume":"18","author":"Dahl","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40264-020-00913-8","article-title":"Sex differences in adverse drug reactions of metformin: a longitudinal survey study","volume":"43","author":"de Vries","year":"2020","journal-title":"Drug Saf."},{"key":"B17","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1093\/jamia\/ocv063","article-title":"Use of data mining at the food and drug administration","volume":"23","author":"Duggirala","year":"2016","journal-title":"J. Am. Med. Inf. Assoc. JAMIA"},{"key":"B18","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/bjh.16278","article-title":"Emergencies in haematology: tumour lysis syndrome","volume":"188","author":"Durani","year":"2020","journal-title":"Br. J. Haematol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet (London, Engl."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.3390\/ijerph9072444","article-title":"Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor","volume":"9","author":"Ezoe","year":"2012","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B22","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1007\/s12325-019-01201-3","article-title":"Sex-related differences in pharmacokinetics and pharmacodynamics of frequently prescribed drugs: a review of the literature","volume":"37","author":"Farkouh","year":"2020","journal-title":"Adv. Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3892\/ol.2022.13610","article-title":"Clinical characteristics of second primary malignancies among first primary malignancy survivors: a single-center study, 2005-2020","volume":"25","author":"Geng","year":"2023","journal-title":"Oncol. Lett."},{"key":"B25","doi-asserted-by":"publisher","first-page":"E515","DOI":"10.1503\/cmaj.221433","article-title":"Tumour lysis syndrome","volume":"195","author":"Grewal","year":"2023","journal-title":"CMAJ Can. Med. Assoc. J. = J. de L'Association Medicale Can."},{"key":"B26","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.toxlet.2010.02.006","article-title":"The FMCA-GM assays, high throughput non-clonogenic alternatives to CFU-GM in preclinical hematotoxicity testing","volume":"194","author":"Haglund","year":"2010","journal-title":"Toxicol. Lett."},{"key":"B27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2165\/00002018-200629030-00005","article-title":"Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile","volume":"29","author":"Hartmann","year":"2006","journal-title":"Drug Saf."},{"key":"B28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/00002018-200326030-00003","article-title":"Quantitative methods in pharmacovigilance: focus on signal detection","volume":"26","author":"Hauben","year":"2003","journal-title":"Drug Saf."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1002\/1878-0261.13035","article-title":"Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis","volume":"15","author":"Helles\u00f8y","year":"2021","journal-title":"Mol. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"438","DOI":"10.2165\/00003495-199039030-00008","article-title":"Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer","volume":"39","author":"Henwood","year":"1990","journal-title":"Drugs"},{"key":"B31","doi-asserted-by":"publisher","first-page":"106601","DOI":"10.1016\/j.intimp.2020.106601","article-title":"Colitis following the use of immune checkpoint inhibitors: a real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system","volume":"84","author":"Hu","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1080\/14740338.2023.2189698","article-title":"Adverse effects of proton pump inhibitors (PPIs) on the renal system using data mining algorithms (DMAs)","volume":"22","author":"Jain","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"B33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2174\/1574886318666230228142856","article-title":"Identification of signal of clindamycin associated renal failure acute: a Disproportionality Analysis","volume":"19","author":"Javed","year":"2023","journal-title":"Curr. Drug Saf."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1002\/cncr.33465","article-title":"Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies","volume":"127","author":"Jeha","year":"2021","journal-title":"Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ijrobp.2006.12.008","article-title":"Influence of interfraction interval on local tumor control in patients with limited-disease small-cell lung cancer treated with radiochemotherapy","volume":"68","author":"Jeremi\u0107","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B36","doi-asserted-by":"publisher","first-page":"11955","DOI":"10.1038\/s41598-020-68906-2","article-title":"Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System","volume":"10","author":"Jiao","year":"2020","journal-title":"Sci. Rep."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/s41409-018-0159-8","article-title":"High-dose Carboplatin\/Etoposide\/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma","volume":"53","author":"Jodele","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"B39","doi-asserted-by":"publisher","first-page":"D1373","DOI":"10.1093\/nar\/gkac956","article-title":"PubChem 2023 update","volume":"51","author":"Kim","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jcpt.13024","article-title":"Time-to-onset analysis of amiodarone-associated thyroid dysfunction","volume":"45","author":"Kinoshita","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"62","DOI":"10.5489\/cuaj.2499","article-title":"Advanced testicular cancer associated with life-threatening tumour lysis syndrome and choriocarcinoma syndrome","volume":"9","author":"Kobatake","year":"2015","journal-title":"Can. Urological Assoc. J. = J. de L'Association Des Urologues Du Can."},{"key":"B42","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review","volume":"25","author":"Kuderer","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/cncr.22004","article-title":"Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma","volume":"107","author":"Kushner","year":"2006","journal-title":"Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41589-022-01236-8","article-title":"Topoisomerase II and etoposide - a tangled tale","volume":"19","author":"Le","year":"2023","journal-title":"Nat. Chem. Biol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.3390\/cancers12123610","article-title":"Second primary malignancy after acute promyelocytic leukemia: a population-based study","volume":"12","author":"Lenzi","year":"2020","journal-title":"Cancers"},{"key":"B46","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2165\/00002018-200023060-00004","article-title":"A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database","volume":"23","author":"Lindquist","year":"2000","journal-title":"Drug Saf."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1158\/1078-0432.CCR-14-2075","article-title":"Bevacizumab preconditioning followed by Etoposide and Cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy","volume":"21","author":"Lu","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ygyno.2014.10.026","article-title":"Phase II trial of oral etoposide plus intravenous irinotecan in patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503)","volume":"136","author":"Matsumoto","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/14712598.2021.1948529","article-title":"The impact of anti-TNF\u03b1 agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database","volume":"21","author":"Mazhar","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1200\/JCO.19.02712","article-title":"Adjuvant chemotherapy with etoposide plus cisplatin for patients with pathologic stage II nonseminomatous germ cell tumors","volume":"38","author":"McHugh","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/annonc\/mdv227","article-title":"Long-term ovarian function in women treated with CHOP or CHOP plus etoposide for aggressive lymphoma","volume":"26","author":"Meissner","year":"2015","journal-title":"Ann. Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e13331","DOI":"10.1111\/ijcp.13331","article-title":"Assessing fluoroquinolone-associated aortic aneurysm and dissection: data mining of the public version of the FDA adverse event reporting system","volume":"73","author":"Meng","year":"2019","journal-title":"Int. J. Clin. Pract."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.2174\/0929867043364531","article-title":"Etoposide: discovery and medicinal chemistry","volume":"11","author":"Meresse","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"B56","doi-asserted-by":"publisher","first-page":"CD003039","DOI":"10.1002\/14651858.CD003039.pub2","article-title":"Colony-stimulating factors for chemotherapy-induced febrile neutropenia","volume":"2014","author":"Mhaskar","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"B57","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.medcli.2019.08.007","article-title":"Adverse drug reactions","volume":"154","author":"Montan\u00e9","year":"2020","journal-title":"Med. Clin."},{"key":"B58","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1056\/NEJMoa1413204","article-title":"Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy","volume":"372","author":"Moore","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.lungcan.2017.02.016","article-title":"A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: the Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial","volume":"108","author":"Morabito","year":"2017","journal-title":"Lung Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"19214","DOI":"10.7448\/IAS.17.1.19214","article-title":"No evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the FAERS database","volume":"17","author":"Napoli","year":"2014","journal-title":"J. Int. AIDS Soc."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/s41409-023-02072-7","article-title":"Implementation and operational management of marketed chimeric antigen receptor T cell (CAR-T Cell) therapy-a guidance by the GoCART Coalition Pharmacist Working Group","volume":"58","author":"Nezvalova-Henriksen","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"B64","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.2147\/DDDT.S81998","article-title":"Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases","volume":"9","author":"Nomura","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"B65","doi-asserted-by":"publisher","first-page":"ofy255","DOI":"10.1093\/ofid\/ofy255","article-title":"Febrile neutropenia and long-term risk of infection among patients treated with chemotherapy for malignant diseases","volume":"5","author":"Nordvig","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"B66","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2165\/00002018-200022040-00002","article-title":"Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention","volume":"22","author":"Pai","year":"2000","journal-title":"Drug Saf."},{"key":"B67","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1200\/JCO.2002.12.065","article-title":"Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate","volume":"20","author":"Papandreou","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.2174\/0929867323666161028162018","article-title":"Clostridium difficile infection: associations with chemotherapy, radiation therapy, and targeting therapy treatments","volume":"23","author":"Peretz","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study","volume":"38","author":"Rudin","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B72","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.1200\/JCO.2006.07.1605","article-title":"Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: west Japan Thoracic Oncology Group 9902","volume":"24","author":"Saito","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s40264-017-0563-9","article-title":"Patients' perspectives on adverse drug reaction reporting in a developing country: a case study from Ghana","volume":"40","author":"Sabblah","year":"2017","journal-title":"Drug Saf."},{"key":"B74","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B75","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","first-page":"750108","DOI":"10.3389\/fphar.2021.750108","article-title":"Kidney injury following ibuprofen and acetaminophen: a real-world analysis of post-marketing surveillance data","volume":"12","author":"Shao","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.addr.2021.04.028","article-title":"The role of sex as a biological variable in the efficacy and toxicity of therapeutic nanomedicine","volume":"174","author":"Sharifi","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B79","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/ane.13690","article-title":"Identification of novel signal of clobazam-associated drug reaction with eosinophilia and systemic symptoms syndrome: a disproportionality analysis","volume":"146","author":"Sharma","year":"2022","journal-title":"Acta Neurol. Scand."},{"key":"B80","doi-asserted-by":"publisher","first-page":"e28671","DOI":"10.1002\/jmv.28671","article-title":"Association of antiviral drugs and their possible mechanisms with DRESS syndrome using data mining algorithms","volume":"95","author":"Sharma","year":"2023","journal-title":"J. Med. Virology"},{"key":"B81","doi-asserted-by":"publisher","first-page":"107195","DOI":"10.1016\/j.lungcan.2023.107195","article-title":"Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: a phase II\/III randomized control trial","volume":"181","author":"Shimokawa","year":"2023","journal-title":"Lung Cancer"},{"key":"B82","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/14740338.2022.2016696","article-title":"A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system","volume":"21","author":"Shu","year":"","journal-title":"Expert Opin. Drug Saf."},{"key":"B83","doi-asserted-by":"publisher","first-page":"862508","DOI":"10.3389\/fphar.2022.862508","article-title":"Post-marketing safety concerns with secukinumab: a disproportionality analysis of the FDA adverse event reporting system","volume":"13","author":"Shu","year":"","journal-title":"Front. Pharmacol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/CLEP.S365513","article-title":"A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system","volume":"14","author":"Shu","year":"","journal-title":"Clin. Epidemiol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"996179","DOI":"10.3389\/fpubh.2022.996179","article-title":"Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system","volume":"10","author":"Shu","year":"","journal-title":"Front. Public Health"},{"key":"B87","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2165\/00148581-200507030-00005","article-title":"Cardiotoxicity of cancer chemotherapy: implications for children","volume":"7","author":"Simbre","year":"2005","journal-title":"Paediatr. Drugs"},{"key":"B88","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cllc.2016.09.002","article-title":"Phase 1\/2 study of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine (IMGN901) in combination with carboplatin\/etoposide in small-cell lung cancer patients with extensive-stage disease","volume":"18","author":"Socinski","year":"2017","journal-title":"Clin. Lung Cancer"},{"key":"B90","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.arbres.2018.01.030","article-title":"Factors affecting lung function: a review of the literature","volume":"54","author":"Talaminos Barroso","year":"2018","journal-title":"Arch. Bronconeumologia"},{"key":"B91","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/S2352-3026(19)30253-4","article-title":"Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations","volume":"7","author":"Tambaro","year":"2020","journal-title":"Lancet. Haematol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"970066","DOI":"10.3389\/fphar.2022.970066","article-title":"Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: a pharmacovigilance study based on FAERS","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s40264-018-0706-7","article-title":"A critical evaluation of safety signal analysis using algorithmic standardised MedDRA queries","volume":"41","author":"Tieu","year":"2018","journal-title":"Drug Saf."},{"key":"B94","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1159\/000440678","article-title":"Carboplatin and etoposide in heavily pretreated patients with progressive high-grade glioma","volume":"60","author":"Tonder","year":"2014","journal-title":"Chemotherapy"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1182\/bloodadvances.2022008543","article-title":"Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL","volume":"7","author":"Torka","year":"2023","journal-title":"Blood Adv."},{"key":"B96","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/S0140-6736(12)60035-X","article-title":"Hodgkin's lymphoma in adults","volume":"380","author":"Townsend","year":"2012","journal-title":"Lancet (London, Engl."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1177\/009127009803801103","article-title":"Gender differences in adverse drug reactions","volume":"38","author":"Tran","year":"1998","journal-title":"J. Clin. Pharmacol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40264-016-0499-5","article-title":"Identification of substandard medicines via disproportionality analysis of individual case safety reports","volume":"40","author":"Trippe","year":"2017","journal-title":"Drug Saf."},{"key":"B99","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1183\/09031936.96.09030596","article-title":"Colony-stimulating factors as an adjunct to chemotherapy in small cell lung cancer","volume":"9","author":"Urban","year":"1996","journal-title":"Eur. Respir. J."},{"key":"B100","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B101","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/sj.bmt.1702812","article-title":"Thrombotic microangiopathy: a new dose-limiting toxicity of high-dose sequential chemotherapy","volume":"27","author":"Vantelon","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"B103","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40264-019-00899-y","article-title":"Investigating overlap in signals from EVDAS, FAERS, and VigiBase","volume":"43","author":"Vogel","year":"2020","journal-title":"Drug Saf."},{"key":"B104","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1007\/s00520-015-2686-9","article-title":"The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Wang","year":"2015","journal-title":"Support. Care Cancer"},{"key":"B106","doi-asserted-by":"publisher","first-page":"101535","DOI":"10.1016\/j.eclinm.2022.101535","article-title":"Toxicity spectrum of immunotherapy in advanced lung cancer: a safety analysis from clinical trials and a pharmacovigilance system","volume":"50","author":"Yan","year":"2022","journal-title":"EClinicalMedicine"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10408363.2016.1191425","article-title":"FDA-approved drugs that interfere with laboratory tests: a systematic search of US drug labels","volume":"54","author":"Yao","year":"2017","journal-title":"Crit. Rev. Clin. Laboratory Sci."},{"key":"B108","doi-asserted-by":"publisher","first-page":"19555","DOI":"10.1038\/s41598-022-23834-1","article-title":"A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib","volume":"12","author":"Yin","year":"2022","journal-title":"Sci. Rep."},{"key":"B109","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.3390\/cancers13112607","article-title":"Childhood cancer: occurrence, treatment and risk of second primary malignancies","volume":"13","author":"Zahnreich","year":"2021","journal-title":"Cancers"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1194545","DOI":"10.3389\/fphar.2023.1194545","article-title":"Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"766125","DOI":"10.3389\/fphar.2021.766125","article-title":"Safety of SGLT2 inhibitors: a pharmacovigilance study from 2013 to 2021 based on FAERS","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.actbio.2015.10.029","article-title":"pH sensitive nano layered double hydroxides reduce the hematotoxicity and enhance the anticancer efficacy of etoposide on non-small cell lung cancer","volume":"29","author":"Zhu","year":"2016","journal-title":"Acta Biomater."},{"key":"B113","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000248311","article-title":"Gender-based differences in drug prescription: relation to adverse drug reactions","volume":"84","author":"Zopf","year":"2009","journal-title":"Pharmacology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1259908\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T09:23:55Z","timestamp":1698312235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1259908\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":99,"alternative-id":["10.3389\/fphar.2023.1259908"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1259908","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]},"article-number":"1259908"}}